Takeda to Acquire Nycomed - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Takeda to Acquire Nycomed


ePT--the Electronic Newsletter of Pharmaceutical Technology

Takeda Pharmaceutical has agreed to acquire Nycomed, a Swiss pharmaceutical company for €9.6 billion ($13.7 billion), excluding Nycomed’s US dermatology business. The deal is intended to increase Takeda’s presence in European and emerging markets.

Nycomed had overall sales of nearly €3.2 billion ($4.5 billion) in fiscal year 2010, and sales of €2.8 billion ($3.9 billion) when excluding its US dermatology business. It is a privately held Zurich-based pharmaceutical company with prescription and over-the-counter products. The acquisition includes the roflumilast franchise, a treatment for chronic obstructive pulmonary disease, which Takeda expects will be a “major source of revenue growth,” according to a May 19, 2011, Takeda press release. Overall, Takeda expects the acquisition to increase its annual revenue by 30%.

The boards of directors of Takeda and Nycomed have agreed to the transaction, as have the shareholders of Nycomed. The deal is expected to close within 90 to 120 days, subject to antitrust approval. Upon closing, Nycomed will become a subsidiary of Takeda. Nycomed is currently owned by the private-equity group Nordic Capital and other investors.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here